Propelled by advances in molecular biology, the cancer vaccine industry is poised for unprecedented growth. This second edition of Kalorama’s groundbreaking 2003 study completely updates the market data and reviews the technological, clinical, and business trends that have shaped and reshaped this emerging field.

Specific segments covered in the report include:

• Cervical cancer,
• Colorectal cancer,
• Lung cancer,
• Lymphoma,
• Melanoma,
• Prostate cancer, and
• Other cancers for which vaccines are in development.

Each market segment provides an overview, descriptions of products available and in development, market estimates and forecasts for 2007-2012 by product, and competitive analysis of leading developers, including forecasted market share for 2012. The report also includes statistical information on cancers by type worldwide and in the United States. Profiles of the following developers and marketers are also included:

• Advaxis, Inc.
• Antigenics, Inc.
• Aphton Corporation
• AVAX Technologies, Inc.
• Biomira, Inc.
• Biovest International, Inc.
• Cell Genesys, Inc.
• Dendreon Corporation
• Favrille, Inc.
• GenMax Corporation
• Genitope Corporation
• Genzyme
• Geron Corporation
• GlaxoSmithKline
• IDM
• Intracel
• Large Scale Biology Corporation
• Medarex, Inc.
• MedImmune, Inc.
• Merck & Company, Inc.
• Northwest Biotherapeutics
• Oxford Biomedica, Plc
• Pharmexa Group
• Progenics Pharmaceuticals, Inc.
• Therion Biologics Corporation
• Vical, Inc.
• YM Biosciences, Inc.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. Kalorama Information conducted interviews with dozens of key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and development representatives.

Related Reports:

Biophotonics: A Strategic Assessment of Photonics Technologies for Biomedical Applications, 2nd Edition
Dec 1, 2008 - KLI1928788 - $3,995.00

Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition
Nov 1, 2008 - KLI1646591 - $3,995.00

SNP Genotyping and Analysis Markets
Jun 1, 2008 - KLI1430117 - $3,995.00

Vaccines 2008: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
Apr 1, 2008 - KLI1682234 - $4,100.00

The Worldwide Market for Cancer Diagnostics, 3rd Edition
Mar 1, 2008 - KLI1393082 - $3,995.00

Analytical Chip Technology: U.S. Markets for Lab on a Chip, DNA/Gene, Protein, and other Microarrays, 3rd. Edition
Nov 1, 2007 - KLI1393085 - $3,995.00

Early Toxicology: Markets and Approaches
Jun 1, 2007 - KLI1300095 - $3,495.00

Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments: World Market
May 1, 2007 - KLI1469934 - $1,995.00

Cancer Therapeutics: The Worldwide Market , 2nd Edition
Feb 1, 2007 - KLI1365882 - $3,995.00

Vaccines: The World Market
Feb 1, 2007 - KLI1351010 - $3,995.00